Sotigalimab

Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma[1][2].

Product Specifications

CAS Number

[2305607-45-6]

Product Name Alternative

APX005M; APX005M; EPI-0050

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sotigalimab.html

Purity

98.90

Solubility

H2O

Smiles

[Sotigalimab]

Molecular Weight

(144.54 kDa)

References & Citations

[1]Mark H O'Hara, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 Jan;22 (1) |[2]Weiss SA, et al. A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. Clin Cancer Res. 2024 Jan 5;30 (1) :74-81.|[3]Filbert EL, et al., APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunol Immunother. 2021 Jul;70 (7) :1853-1865.